Review




Structured Review

BioFire Defense filmarray respiratory 2 (rp2) panel
Filmarray Respiratory 2 (Rp2) Panel, supplied by BioFire Defense, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/respiratory+panel+2+(rp2/filmarray+respiratory+panel/pm38666607-6-23-22
Average 90 stars, based on 1 article reviews
filmarray respiratory 2 (rp2) panel - by Bioz Stars, 2026-09
90/100 stars

Images

Related Articles

Diagnostic Assay:

Article Title: P-2177. The Prevalence of Respiratory Viral Pathogen Detection on Nasopharyngeal Specimens Evaluated by Multiplex Polymerase Chain Reaction Among Asymptomatic Children
Article Snippet: Participant Findings by Multiplex PCR Positivity in 20 Peds RECON Participants at Enrollment Legend: += positive -= Negative ^= Rhinovirus/Enterovirus and Parainfluenza 3 #=Number NS= not significant, p-value ≥ 0.05 Peds RECON- Pediatric Respiratory Co-infection and Immunologic Response Study NP= Nasopharyngeal (NP) M-PCR= Multiplex Polymerase Chain Reaction, Nasopharyngeal specimens were processed using the BioFire® Respiratory 2.1 (RP2.1) Panel PBMC=Peripheral Blood Mononuclear Cells

Article Title: P-2177. The Prevalence of Respiratory Viral Pathogen Detection on Nasopharyngeal Specimens Evaluated by Multiplex Polymerase Chain Reaction Among Asymptomatic Children
Article Snippet: Demographic and Clinical Characteristics of 20 Children at Enrollment in the Pediatric Respiratory Co-infection and Immunologic Response Study (Peds RECON) Legend: ^= Nasopharyngeal specimens were processed using the BioFire® Respiratory 2.1 (RP2.1) Panel * = within 10 days of the participant’s enrollment visit + = Symptoms queried: fever, headache, runny or dripping nose, sore or painful throat, trouble breathing/shortness of breath, chest tightness/pain, dizziness, coughing, nausea, vomiting, diarrhea, clingy, fussy, decreased energy level #= Among 15 participants where blood sample was available; 4 of 7 participants with positive M-PCR and 11 of 13 participants with negative M-PCR NP=Nasopharyngeal; SD= Standard deviation; M- PCR= Multiplex Polymerase Chain Reaction

Article Title: Evaluation of molecular detection for respiratory syncytial viruses in World Health Organization Europe region laboratories, 2020-2023.
Article Snippet: For bioMérieux, not only are there different assays, but also different diagnostic platforms: SARS-CoV-2 FluA/FluB/RSV R-Gene for qRT-PCR hardware, or the Respiratory 2.1 (RP2.1) Panel for the Biofire.

Article Title: Multicenter Evaluation of the QIAstat‐Dx and the BioFire Multiplex Panel Tests for the Detection of Respiratory Pathogens
Article Snippet: Among those are the BioFire respiratory multiplex panel version 2.1 (BioFire‐RP2.1) and the QIAstat‐Dx respiratory panel version 2.0 (QIAstat‐Dx‐RP2.0), generating results from 23 different respiratory targets, including SARS‐CoV‐2 in approximately 1 h. In this prospective multicenter study, we conducted a comparative evaluation of the BioFire‐RP2.1 and QIAstat‐Dx‐RP2.0 multiplex panel tests using 269 respiratory clinical specimens, prospectively collected from patients with RTIs.

Article Title: Performance Assessment of a Multiplex Real-Time PCR Assay for Detection of Viruses Causing Respiratory Tract Infections
Article Snippet: We further compared the performance of this test to two different multiplex PCR-based platforms, which detect SARS-CoV-2, Flu A, Flu B, and RSV in a single reaction: an LDT that is based on a TaqMan ® real-time OpenArray ® PCR platform and an FDA-approved in vitro diagnostic (IVD) test, the BioFire ® Respiratory 2.1 (RP2.1) Panel.

Article Title: Clinical Features and Genomic Characteristics of Post-pandemic Human Metapneumovirus Infections in Hospitalized Taiwanese Children
Article Snippet: 76 In Study 2, we retrieved medical records retrospectively from all hospitalized HMPV-77 infected children confirmed either by the BIOFIRE® Respiratory 2.1 (RP2.1) Panel or 78 the above-mentioned study.

Article Title: Performance Assessment of a Multiplex Real-Time PCR Assay for Detection of Viruses Causing Respiratory Tract Infections
Article Snippet: While the BioFire ® Respiratory 2.1 (RP2.1) Panel mainly detects viral pathogens associated with respiratory illnesses and four bacterial causes of atypical pneumonia, the OA LDT covers, in addition, a broader range of bacterial pathogens involved in respiratory tract infections.

Article Title: Multicenter Evaluation of the QIAstat-Dx and the BioFire Multiplex Panel Tests for the Detection of Respiratory Pathogens.
Article Snippet: Among those are the BioFire respiratory multiplex panel version 2.1 (BioFire‐RP2.1) and the QIAstat‐Dx respiratory panel version 2.0 (QIAstat‐Dx‐RP2.0), generating results from 23 different respiratory targets, including SARS‐CoV‐2 in approximately 1 h. In this prospective multicenter study, we conducted a comparative evaluation of the BioFire‐RP2.1 and QIAstat‐Dx‐RP2.0 multiplex panel tests using 269 respiratory clinical specimens, prospectively collected from patients with RTIs.

Quantitative RT-PCR:

Article Title: P-2177. The Prevalence of Respiratory Viral Pathogen Detection on Nasopharyngeal Specimens Evaluated by Multiplex Polymerase Chain Reaction Among Asymptomatic Children
Article Snippet: Participant Findings by Multiplex PCR Positivity in 20 Peds RECON Participants at Enrollment Legend: += positive -= Negative ^= Rhinovirus/Enterovirus and Parainfluenza 3 #=Number NS= not significant, p-value ≥ 0.05 Peds RECON- Pediatric Respiratory Co-infection and Immunologic Response Study NP= Nasopharyngeal (NP) M-PCR= Multiplex Polymerase Chain Reaction, Nasopharyngeal specimens were processed using the BioFire® Respiratory 2.1 (RP2.1) Panel PBMC=Peripheral Blood Mononuclear Cells

Article Title: P-2177. The Prevalence of Respiratory Viral Pathogen Detection on Nasopharyngeal Specimens Evaluated by Multiplex Polymerase Chain Reaction Among Asymptomatic Children
Article Snippet: Demographic and Clinical Characteristics of 20 Children at Enrollment in the Pediatric Respiratory Co-infection and Immunologic Response Study (Peds RECON) Legend: ^= Nasopharyngeal specimens were processed using the BioFire® Respiratory 2.1 (RP2.1) Panel * = within 10 days of the participant’s enrollment visit + = Symptoms queried: fever, headache, runny or dripping nose, sore or painful throat, trouble breathing/shortness of breath, chest tightness/pain, dizziness, coughing, nausea, vomiting, diarrhea, clingy, fussy, decreased energy level #= Among 15 participants where blood sample was available; 4 of 7 participants with positive M-PCR and 11 of 13 participants with negative M-PCR NP=Nasopharyngeal; SD= Standard deviation; M- PCR= Multiplex Polymerase Chain Reaction

Article Title: Evaluation of molecular detection for respiratory syncytial viruses in World Health Organization Europe region laboratories, 2020-2023.
Article Snippet: For bioMérieux, not only are there different assays, but also different diagnostic platforms: SARS-CoV-2 FluA/FluB/RSV R-Gene for qRT-PCR hardware, or the Respiratory 2.1 (RP2.1) Panel for the Biofire.

Article Title: Multicenter Evaluation of the QIAstat‐Dx and the BioFire Multiplex Panel Tests for the Detection of Respiratory Pathogens
Article Snippet: Among those are the BioFire respiratory multiplex panel version 2.1 (BioFire‐RP2.1) and the QIAstat‐Dx respiratory panel version 2.0 (QIAstat‐Dx‐RP2.0), generating results from 23 different respiratory targets, including SARS‐CoV‐2 in approximately 1 h. In this prospective multicenter study, we conducted a comparative evaluation of the BioFire‐RP2.1 and QIAstat‐Dx‐RP2.0 multiplex panel tests using 269 respiratory clinical specimens, prospectively collected from patients with RTIs.

Article Title: Performance Assessment of a Multiplex Real-Time PCR Assay for Detection of Viruses Causing Respiratory Tract Infections
Article Snippet: We further compared the performance of this test to two different multiplex PCR-based platforms, which detect SARS-CoV-2, Flu A, Flu B, and RSV in a single reaction: an LDT that is based on a TaqMan ® real-time OpenArray ® PCR platform and an FDA-approved in vitro diagnostic (IVD) test, the BioFire ® Respiratory 2.1 (RP2.1) Panel.

Article Title: Clinical Features and Genomic Characteristics of Post-pandemic Human Metapneumovirus Infections in Hospitalized Taiwanese Children
Article Snippet: 76 In Study 2, we retrieved medical records retrospectively from all hospitalized HMPV-77 infected children confirmed either by the BIOFIRE® Respiratory 2.1 (RP2.1) Panel or 78 the above-mentioned study.

Article Title: Performance Assessment of a Multiplex Real-Time PCR Assay for Detection of Viruses Causing Respiratory Tract Infections
Article Snippet: While the BioFire ® Respiratory 2.1 (RP2.1) Panel mainly detects viral pathogens associated with respiratory illnesses and four bacterial causes of atypical pneumonia, the OA LDT covers, in addition, a broader range of bacterial pathogens involved in respiratory tract infections.

Article Title: Multicenter Evaluation of the QIAstat-Dx and the BioFire Multiplex Panel Tests for the Detection of Respiratory Pathogens.
Article Snippet: Among those are the BioFire respiratory multiplex panel version 2.1 (BioFire‐RP2.1) and the QIAstat‐Dx respiratory panel version 2.0 (QIAstat‐Dx‐RP2.0), generating results from 23 different respiratory targets, including SARS‐CoV‐2 in approximately 1 h. In this prospective multicenter study, we conducted a comparative evaluation of the BioFire‐RP2.1 and QIAstat‐Dx‐RP2.0 multiplex panel tests using 269 respiratory clinical specimens, prospectively collected from patients with RTIs.

Standard Deviation:

Article Title: P-2177. The Prevalence of Respiratory Viral Pathogen Detection on Nasopharyngeal Specimens Evaluated by Multiplex Polymerase Chain Reaction Among Asymptomatic Children
Article Snippet: Participant Findings by Multiplex PCR Positivity in 20 Peds RECON Participants at Enrollment Legend: += positive -= Negative ^= Rhinovirus/Enterovirus and Parainfluenza 3 #=Number NS= not significant, p-value ≥ 0.05 Peds RECON- Pediatric Respiratory Co-infection and Immunologic Response Study NP= Nasopharyngeal (NP) M-PCR= Multiplex Polymerase Chain Reaction, Nasopharyngeal specimens were processed using the BioFire® Respiratory 2.1 (RP2.1) Panel PBMC=Peripheral Blood Mononuclear Cells

Article Title: P-2177. The Prevalence of Respiratory Viral Pathogen Detection on Nasopharyngeal Specimens Evaluated by Multiplex Polymerase Chain Reaction Among Asymptomatic Children
Article Snippet: Demographic and Clinical Characteristics of 20 Children at Enrollment in the Pediatric Respiratory Co-infection and Immunologic Response Study (Peds RECON) Legend: ^= Nasopharyngeal specimens were processed using the BioFire® Respiratory 2.1 (RP2.1) Panel * = within 10 days of the participant’s enrollment visit + = Symptoms queried: fever, headache, runny or dripping nose, sore or painful throat, trouble breathing/shortness of breath, chest tightness/pain, dizziness, coughing, nausea, vomiting, diarrhea, clingy, fussy, decreased energy level #= Among 15 participants where blood sample was available; 4 of 7 participants with positive M-PCR and 11 of 13 participants with negative M-PCR NP=Nasopharyngeal; SD= Standard deviation; M- PCR= Multiplex Polymerase Chain Reaction

Article Title: Evaluation of molecular detection for respiratory syncytial viruses in World Health Organization Europe region laboratories, 2020-2023.
Article Snippet: For bioMérieux, not only are there different assays, but also different diagnostic platforms: SARS-CoV-2 FluA/FluB/RSV R-Gene for qRT-PCR hardware, or the Respiratory 2.1 (RP2.1) Panel for the Biofire.

Article Title: Multicenter Evaluation of the QIAstat‐Dx and the BioFire Multiplex Panel Tests for the Detection of Respiratory Pathogens
Article Snippet: Among those are the BioFire respiratory multiplex panel version 2.1 (BioFire‐RP2.1) and the QIAstat‐Dx respiratory panel version 2.0 (QIAstat‐Dx‐RP2.0), generating results from 23 different respiratory targets, including SARS‐CoV‐2 in approximately 1 h. In this prospective multicenter study, we conducted a comparative evaluation of the BioFire‐RP2.1 and QIAstat‐Dx‐RP2.0 multiplex panel tests using 269 respiratory clinical specimens, prospectively collected from patients with RTIs.

Article Title: Performance Assessment of a Multiplex Real-Time PCR Assay for Detection of Viruses Causing Respiratory Tract Infections
Article Snippet: We further compared the performance of this test to two different multiplex PCR-based platforms, which detect SARS-CoV-2, Flu A, Flu B, and RSV in a single reaction: an LDT that is based on a TaqMan ® real-time OpenArray ® PCR platform and an FDA-approved in vitro diagnostic (IVD) test, the BioFire ® Respiratory 2.1 (RP2.1) Panel.

Article Title: Clinical Features and Genomic Characteristics of Post-pandemic Human Metapneumovirus Infections in Hospitalized Taiwanese Children
Article Snippet: 76 In Study 2, we retrieved medical records retrospectively from all hospitalized HMPV-77 infected children confirmed either by the BIOFIRE® Respiratory 2.1 (RP2.1) Panel or 78 the above-mentioned study.

Article Title: Performance Assessment of a Multiplex Real-Time PCR Assay for Detection of Viruses Causing Respiratory Tract Infections
Article Snippet: While the BioFire ® Respiratory 2.1 (RP2.1) Panel mainly detects viral pathogens associated with respiratory illnesses and four bacterial causes of atypical pneumonia, the OA LDT covers, in addition, a broader range of bacterial pathogens involved in respiratory tract infections.

Article Title: Multicenter Evaluation of the QIAstat-Dx and the BioFire Multiplex Panel Tests for the Detection of Respiratory Pathogens.
Article Snippet: Among those are the BioFire respiratory multiplex panel version 2.1 (BioFire‐RP2.1) and the QIAstat‐Dx respiratory panel version 2.0 (QIAstat‐Dx‐RP2.0), generating results from 23 different respiratory targets, including SARS‐CoV‐2 in approximately 1 h. In this prospective multicenter study, we conducted a comparative evaluation of the BioFire‐RP2.1 and QIAstat‐Dx‐RP2.0 multiplex panel tests using 269 respiratory clinical specimens, prospectively collected from patients with RTIs.

Polymerase Chain Reaction:

Article Title: P-2177. The Prevalence of Respiratory Viral Pathogen Detection on Nasopharyngeal Specimens Evaluated by Multiplex Polymerase Chain Reaction Among Asymptomatic Children
Article Snippet: Participant Findings by Multiplex PCR Positivity in 20 Peds RECON Participants at Enrollment Legend: += positive -= Negative ^= Rhinovirus/Enterovirus and Parainfluenza 3 #=Number NS= not significant, p-value ≥ 0.05 Peds RECON- Pediatric Respiratory Co-infection and Immunologic Response Study NP= Nasopharyngeal (NP) M-PCR= Multiplex Polymerase Chain Reaction, Nasopharyngeal specimens were processed using the BioFire® Respiratory 2.1 (RP2.1) Panel PBMC=Peripheral Blood Mononuclear Cells

Article Title: P-2177. The Prevalence of Respiratory Viral Pathogen Detection on Nasopharyngeal Specimens Evaluated by Multiplex Polymerase Chain Reaction Among Asymptomatic Children
Article Snippet: Demographic and Clinical Characteristics of 20 Children at Enrollment in the Pediatric Respiratory Co-infection and Immunologic Response Study (Peds RECON) Legend: ^= Nasopharyngeal specimens were processed using the BioFire® Respiratory 2.1 (RP2.1) Panel * = within 10 days of the participant’s enrollment visit + = Symptoms queried: fever, headache, runny or dripping nose, sore or painful throat, trouble breathing/shortness of breath, chest tightness/pain, dizziness, coughing, nausea, vomiting, diarrhea, clingy, fussy, decreased energy level #= Among 15 participants where blood sample was available; 4 of 7 participants with positive M-PCR and 11 of 13 participants with negative M-PCR NP=Nasopharyngeal; SD= Standard deviation; M- PCR= Multiplex Polymerase Chain Reaction

Article Title: Evaluation of molecular detection for respiratory syncytial viruses in World Health Organization Europe region laboratories, 2020-2023.
Article Snippet: For bioMérieux, not only are there different assays, but also different diagnostic platforms: SARS-CoV-2 FluA/FluB/RSV R-Gene for qRT-PCR hardware, or the Respiratory 2.1 (RP2.1) Panel for the Biofire.

Article Title: Multicenter Evaluation of the QIAstat‐Dx and the BioFire Multiplex Panel Tests for the Detection of Respiratory Pathogens
Article Snippet: Among those are the BioFire respiratory multiplex panel version 2.1 (BioFire‐RP2.1) and the QIAstat‐Dx respiratory panel version 2.0 (QIAstat‐Dx‐RP2.0), generating results from 23 different respiratory targets, including SARS‐CoV‐2 in approximately 1 h. In this prospective multicenter study, we conducted a comparative evaluation of the BioFire‐RP2.1 and QIAstat‐Dx‐RP2.0 multiplex panel tests using 269 respiratory clinical specimens, prospectively collected from patients with RTIs.

Article Title: Performance Assessment of a Multiplex Real-Time PCR Assay for Detection of Viruses Causing Respiratory Tract Infections
Article Snippet: We further compared the performance of this test to two different multiplex PCR-based platforms, which detect SARS-CoV-2, Flu A, Flu B, and RSV in a single reaction: an LDT that is based on a TaqMan ® real-time OpenArray ® PCR platform and an FDA-approved in vitro diagnostic (IVD) test, the BioFire ® Respiratory 2.1 (RP2.1) Panel.

Article Title: Clinical Features and Genomic Characteristics of Post-pandemic Human Metapneumovirus Infections in Hospitalized Taiwanese Children
Article Snippet: 76 In Study 2, we retrieved medical records retrospectively from all hospitalized HMPV-77 infected children confirmed either by the BIOFIRE® Respiratory 2.1 (RP2.1) Panel or 78 the above-mentioned study.

Article Title: Performance Assessment of a Multiplex Real-Time PCR Assay for Detection of Viruses Causing Respiratory Tract Infections
Article Snippet: While the BioFire ® Respiratory 2.1 (RP2.1) Panel mainly detects viral pathogens associated with respiratory illnesses and four bacterial causes of atypical pneumonia, the OA LDT covers, in addition, a broader range of bacterial pathogens involved in respiratory tract infections.

Article Title: Multicenter Evaluation of the QIAstat-Dx and the BioFire Multiplex Panel Tests for the Detection of Respiratory Pathogens.
Article Snippet: Among those are the BioFire respiratory multiplex panel version 2.1 (BioFire‐RP2.1) and the QIAstat‐Dx respiratory panel version 2.0 (QIAstat‐Dx‐RP2.0), generating results from 23 different respiratory targets, including SARS‐CoV‐2 in approximately 1 h. In this prospective multicenter study, we conducted a comparative evaluation of the BioFire‐RP2.1 and QIAstat‐Dx‐RP2.0 multiplex panel tests using 269 respiratory clinical specimens, prospectively collected from patients with RTIs.

Multiplex Assay:

Article Title: P-2177. The Prevalence of Respiratory Viral Pathogen Detection on Nasopharyngeal Specimens Evaluated by Multiplex Polymerase Chain Reaction Among Asymptomatic Children
Article Snippet: Participant Findings by Multiplex PCR Positivity in 20 Peds RECON Participants at Enrollment Legend: += positive -= Negative ^= Rhinovirus/Enterovirus and Parainfluenza 3 #=Number NS= not significant, p-value ≥ 0.05 Peds RECON- Pediatric Respiratory Co-infection and Immunologic Response Study NP= Nasopharyngeal (NP) M-PCR= Multiplex Polymerase Chain Reaction, Nasopharyngeal specimens were processed using the BioFire® Respiratory 2.1 (RP2.1) Panel PBMC=Peripheral Blood Mononuclear Cells

Article Title: P-2177. The Prevalence of Respiratory Viral Pathogen Detection on Nasopharyngeal Specimens Evaluated by Multiplex Polymerase Chain Reaction Among Asymptomatic Children
Article Snippet: Demographic and Clinical Characteristics of 20 Children at Enrollment in the Pediatric Respiratory Co-infection and Immunologic Response Study (Peds RECON) Legend: ^= Nasopharyngeal specimens were processed using the BioFire® Respiratory 2.1 (RP2.1) Panel * = within 10 days of the participant’s enrollment visit + = Symptoms queried: fever, headache, runny or dripping nose, sore or painful throat, trouble breathing/shortness of breath, chest tightness/pain, dizziness, coughing, nausea, vomiting, diarrhea, clingy, fussy, decreased energy level #= Among 15 participants where blood sample was available; 4 of 7 participants with positive M-PCR and 11 of 13 participants with negative M-PCR NP=Nasopharyngeal; SD= Standard deviation; M- PCR= Multiplex Polymerase Chain Reaction

Article Title: Evaluation of molecular detection for respiratory syncytial viruses in World Health Organization Europe region laboratories, 2020-2023.
Article Snippet: For bioMérieux, not only are there different assays, but also different diagnostic platforms: SARS-CoV-2 FluA/FluB/RSV R-Gene for qRT-PCR hardware, or the Respiratory 2.1 (RP2.1) Panel for the Biofire.

Article Title: Multicenter Evaluation of the QIAstat‐Dx and the BioFire Multiplex Panel Tests for the Detection of Respiratory Pathogens
Article Snippet: Among those are the BioFire respiratory multiplex panel version 2.1 (BioFire‐RP2.1) and the QIAstat‐Dx respiratory panel version 2.0 (QIAstat‐Dx‐RP2.0), generating results from 23 different respiratory targets, including SARS‐CoV‐2 in approximately 1 h. In this prospective multicenter study, we conducted a comparative evaluation of the BioFire‐RP2.1 and QIAstat‐Dx‐RP2.0 multiplex panel tests using 269 respiratory clinical specimens, prospectively collected from patients with RTIs.

Article Title: Performance Assessment of a Multiplex Real-Time PCR Assay for Detection of Viruses Causing Respiratory Tract Infections
Article Snippet: We further compared the performance of this test to two different multiplex PCR-based platforms, which detect SARS-CoV-2, Flu A, Flu B, and RSV in a single reaction: an LDT that is based on a TaqMan ® real-time OpenArray ® PCR platform and an FDA-approved in vitro diagnostic (IVD) test, the BioFire ® Respiratory 2.1 (RP2.1) Panel.

Article Title: Clinical Features and Genomic Characteristics of Post-pandemic Human Metapneumovirus Infections in Hospitalized Taiwanese Children
Article Snippet: 76 In Study 2, we retrieved medical records retrospectively from all hospitalized HMPV-77 infected children confirmed either by the BIOFIRE® Respiratory 2.1 (RP2.1) Panel or 78 the above-mentioned study.

Article Title: Performance Assessment of a Multiplex Real-Time PCR Assay for Detection of Viruses Causing Respiratory Tract Infections
Article Snippet: While the BioFire ® Respiratory 2.1 (RP2.1) Panel mainly detects viral pathogens associated with respiratory illnesses and four bacterial causes of atypical pneumonia, the OA LDT covers, in addition, a broader range of bacterial pathogens involved in respiratory tract infections.

Article Title: Multicenter Evaluation of the QIAstat-Dx and the BioFire Multiplex Panel Tests for the Detection of Respiratory Pathogens.
Article Snippet: Among those are the BioFire respiratory multiplex panel version 2.1 (BioFire‐RP2.1) and the QIAstat‐Dx respiratory panel version 2.0 (QIAstat‐Dx‐RP2.0), generating results from 23 different respiratory targets, including SARS‐CoV‐2 in approximately 1 h. In this prospective multicenter study, we conducted a comparative evaluation of the BioFire‐RP2.1 and QIAstat‐Dx‐RP2.0 multiplex panel tests using 269 respiratory clinical specimens, prospectively collected from patients with RTIs.

Significance Assay:

Article Title: P-2177. The Prevalence of Respiratory Viral Pathogen Detection on Nasopharyngeal Specimens Evaluated by Multiplex Polymerase Chain Reaction Among Asymptomatic Children
Article Snippet: Participant Findings by Multiplex PCR Positivity in 20 Peds RECON Participants at Enrollment Legend: += positive -= Negative ^= Rhinovirus/Enterovirus and Parainfluenza 3 #=Number NS= not significant, p-value ≥ 0.05 Peds RECON- Pediatric Respiratory Co-infection and Immunologic Response Study NP= Nasopharyngeal (NP) M-PCR= Multiplex Polymerase Chain Reaction, Nasopharyngeal specimens were processed using the BioFire® Respiratory 2.1 (RP2.1) Panel PBMC=Peripheral Blood Mononuclear Cells

Article Title: P-2177. The Prevalence of Respiratory Viral Pathogen Detection on Nasopharyngeal Specimens Evaluated by Multiplex Polymerase Chain Reaction Among Asymptomatic Children
Article Snippet: Demographic and Clinical Characteristics of 20 Children at Enrollment in the Pediatric Respiratory Co-infection and Immunologic Response Study (Peds RECON) Legend: ^= Nasopharyngeal specimens were processed using the BioFire® Respiratory 2.1 (RP2.1) Panel * = within 10 days of the participant’s enrollment visit + = Symptoms queried: fever, headache, runny or dripping nose, sore or painful throat, trouble breathing/shortness of breath, chest tightness/pain, dizziness, coughing, nausea, vomiting, diarrhea, clingy, fussy, decreased energy level #= Among 15 participants where blood sample was available; 4 of 7 participants with positive M-PCR and 11 of 13 participants with negative M-PCR NP=Nasopharyngeal; SD= Standard deviation; M- PCR= Multiplex Polymerase Chain Reaction

Article Title: Evaluation of molecular detection for respiratory syncytial viruses in World Health Organization Europe region laboratories, 2020-2023.
Article Snippet: For bioMérieux, not only are there different assays, but also different diagnostic platforms: SARS-CoV-2 FluA/FluB/RSV R-Gene for qRT-PCR hardware, or the Respiratory 2.1 (RP2.1) Panel for the Biofire.

Article Title: Multicenter Evaluation of the QIAstat‐Dx and the BioFire Multiplex Panel Tests for the Detection of Respiratory Pathogens
Article Snippet: Among those are the BioFire respiratory multiplex panel version 2.1 (BioFire‐RP2.1) and the QIAstat‐Dx respiratory panel version 2.0 (QIAstat‐Dx‐RP2.0), generating results from 23 different respiratory targets, including SARS‐CoV‐2 in approximately 1 h. In this prospective multicenter study, we conducted a comparative evaluation of the BioFire‐RP2.1 and QIAstat‐Dx‐RP2.0 multiplex panel tests using 269 respiratory clinical specimens, prospectively collected from patients with RTIs.

Article Title: Performance Assessment of a Multiplex Real-Time PCR Assay for Detection of Viruses Causing Respiratory Tract Infections
Article Snippet: We further compared the performance of this test to two different multiplex PCR-based platforms, which detect SARS-CoV-2, Flu A, Flu B, and RSV in a single reaction: an LDT that is based on a TaqMan ® real-time OpenArray ® PCR platform and an FDA-approved in vitro diagnostic (IVD) test, the BioFire ® Respiratory 2.1 (RP2.1) Panel.

Article Title: Clinical Features and Genomic Characteristics of Post-pandemic Human Metapneumovirus Infections in Hospitalized Taiwanese Children
Article Snippet: 76 In Study 2, we retrieved medical records retrospectively from all hospitalized HMPV-77 infected children confirmed either by the BIOFIRE® Respiratory 2.1 (RP2.1) Panel or 78 the above-mentioned study.

Article Title: Performance Assessment of a Multiplex Real-Time PCR Assay for Detection of Viruses Causing Respiratory Tract Infections
Article Snippet: While the BioFire ® Respiratory 2.1 (RP2.1) Panel mainly detects viral pathogens associated with respiratory illnesses and four bacterial causes of atypical pneumonia, the OA LDT covers, in addition, a broader range of bacterial pathogens involved in respiratory tract infections.

Article Title: Multicenter Evaluation of the QIAstat-Dx and the BioFire Multiplex Panel Tests for the Detection of Respiratory Pathogens.
Article Snippet: Among those are the BioFire respiratory multiplex panel version 2.1 (BioFire‐RP2.1) and the QIAstat‐Dx respiratory panel version 2.0 (QIAstat‐Dx‐RP2.0), generating results from 23 different respiratory targets, including SARS‐CoV‐2 in approximately 1 h. In this prospective multicenter study, we conducted a comparative evaluation of the BioFire‐RP2.1 and QIAstat‐Dx‐RP2.0 multiplex panel tests using 269 respiratory clinical specimens, prospectively collected from patients with RTIs.

MANN-WHITNEY:

Article Title: P-2177. The Prevalence of Respiratory Viral Pathogen Detection on Nasopharyngeal Specimens Evaluated by Multiplex Polymerase Chain Reaction Among Asymptomatic Children
Article Snippet: Participant Findings by Multiplex PCR Positivity in 20 Peds RECON Participants at Enrollment Legend: += positive -= Negative ^= Rhinovirus/Enterovirus and Parainfluenza 3 #=Number NS= not significant, p-value ≥ 0.05 Peds RECON- Pediatric Respiratory Co-infection and Immunologic Response Study NP= Nasopharyngeal (NP) M-PCR= Multiplex Polymerase Chain Reaction, Nasopharyngeal specimens were processed using the BioFire® Respiratory 2.1 (RP2.1) Panel PBMC=Peripheral Blood Mononuclear Cells

Article Title: P-2177. The Prevalence of Respiratory Viral Pathogen Detection on Nasopharyngeal Specimens Evaluated by Multiplex Polymerase Chain Reaction Among Asymptomatic Children
Article Snippet: Demographic and Clinical Characteristics of 20 Children at Enrollment in the Pediatric Respiratory Co-infection and Immunologic Response Study (Peds RECON) Legend: ^= Nasopharyngeal specimens were processed using the BioFire® Respiratory 2.1 (RP2.1) Panel * = within 10 days of the participant’s enrollment visit + = Symptoms queried: fever, headache, runny or dripping nose, sore or painful throat, trouble breathing/shortness of breath, chest tightness/pain, dizziness, coughing, nausea, vomiting, diarrhea, clingy, fussy, decreased energy level #= Among 15 participants where blood sample was available; 4 of 7 participants with positive M-PCR and 11 of 13 participants with negative M-PCR NP=Nasopharyngeal; SD= Standard deviation; M- PCR= Multiplex Polymerase Chain Reaction

Article Title: Evaluation of molecular detection for respiratory syncytial viruses in World Health Organization Europe region laboratories, 2020-2023.
Article Snippet: For bioMérieux, not only are there different assays, but also different diagnostic platforms: SARS-CoV-2 FluA/FluB/RSV R-Gene for qRT-PCR hardware, or the Respiratory 2.1 (RP2.1) Panel for the Biofire.

Article Title: Multicenter Evaluation of the QIAstat‐Dx and the BioFire Multiplex Panel Tests for the Detection of Respiratory Pathogens
Article Snippet: Among those are the BioFire respiratory multiplex panel version 2.1 (BioFire‐RP2.1) and the QIAstat‐Dx respiratory panel version 2.0 (QIAstat‐Dx‐RP2.0), generating results from 23 different respiratory targets, including SARS‐CoV‐2 in approximately 1 h. In this prospective multicenter study, we conducted a comparative evaluation of the BioFire‐RP2.1 and QIAstat‐Dx‐RP2.0 multiplex panel tests using 269 respiratory clinical specimens, prospectively collected from patients with RTIs.

Article Title: Performance Assessment of a Multiplex Real-Time PCR Assay for Detection of Viruses Causing Respiratory Tract Infections
Article Snippet: We further compared the performance of this test to two different multiplex PCR-based platforms, which detect SARS-CoV-2, Flu A, Flu B, and RSV in a single reaction: an LDT that is based on a TaqMan ® real-time OpenArray ® PCR platform and an FDA-approved in vitro diagnostic (IVD) test, the BioFire ® Respiratory 2.1 (RP2.1) Panel.

Article Title: Clinical Features and Genomic Characteristics of Post-pandemic Human Metapneumovirus Infections in Hospitalized Taiwanese Children
Article Snippet: 76 In Study 2, we retrieved medical records retrospectively from all hospitalized HMPV-77 infected children confirmed either by the BIOFIRE® Respiratory 2.1 (RP2.1) Panel or 78 the above-mentioned study.

Article Title: Performance Assessment of a Multiplex Real-Time PCR Assay for Detection of Viruses Causing Respiratory Tract Infections
Article Snippet: While the BioFire ® Respiratory 2.1 (RP2.1) Panel mainly detects viral pathogens associated with respiratory illnesses and four bacterial causes of atypical pneumonia, the OA LDT covers, in addition, a broader range of bacterial pathogens involved in respiratory tract infections.

Article Title: Multicenter Evaluation of the QIAstat-Dx and the BioFire Multiplex Panel Tests for the Detection of Respiratory Pathogens.
Article Snippet: Among those are the BioFire respiratory multiplex panel version 2.1 (BioFire‐RP2.1) and the QIAstat‐Dx respiratory panel version 2.0 (QIAstat‐Dx‐RP2.0), generating results from 23 different respiratory targets, including SARS‐CoV‐2 in approximately 1 h. In this prospective multicenter study, we conducted a comparative evaluation of the BioFire‐RP2.1 and QIAstat‐Dx‐RP2.0 multiplex panel tests using 269 respiratory clinical specimens, prospectively collected from patients with RTIs.

Virus:

Article Title: P-2177. The Prevalence of Respiratory Viral Pathogen Detection on Nasopharyngeal Specimens Evaluated by Multiplex Polymerase Chain Reaction Among Asymptomatic Children
Article Snippet: Participant Findings by Multiplex PCR Positivity in 20 Peds RECON Participants at Enrollment Legend: += positive -= Negative ^= Rhinovirus/Enterovirus and Parainfluenza 3 #=Number NS= not significant, p-value ≥ 0.05 Peds RECON- Pediatric Respiratory Co-infection and Immunologic Response Study NP= Nasopharyngeal (NP) M-PCR= Multiplex Polymerase Chain Reaction, Nasopharyngeal specimens were processed using the BioFire® Respiratory 2.1 (RP2.1) Panel PBMC=Peripheral Blood Mononuclear Cells

Article Title: P-2177. The Prevalence of Respiratory Viral Pathogen Detection on Nasopharyngeal Specimens Evaluated by Multiplex Polymerase Chain Reaction Among Asymptomatic Children
Article Snippet: Demographic and Clinical Characteristics of 20 Children at Enrollment in the Pediatric Respiratory Co-infection and Immunologic Response Study (Peds RECON) Legend: ^= Nasopharyngeal specimens were processed using the BioFire® Respiratory 2.1 (RP2.1) Panel * = within 10 days of the participant’s enrollment visit + = Symptoms queried: fever, headache, runny or dripping nose, sore or painful throat, trouble breathing/shortness of breath, chest tightness/pain, dizziness, coughing, nausea, vomiting, diarrhea, clingy, fussy, decreased energy level #= Among 15 participants where blood sample was available; 4 of 7 participants with positive M-PCR and 11 of 13 participants with negative M-PCR NP=Nasopharyngeal; SD= Standard deviation; M- PCR= Multiplex Polymerase Chain Reaction

Article Title: Evaluation of molecular detection for respiratory syncytial viruses in World Health Organization Europe region laboratories, 2020-2023.
Article Snippet: For bioMérieux, not only are there different assays, but also different diagnostic platforms: SARS-CoV-2 FluA/FluB/RSV R-Gene for qRT-PCR hardware, or the Respiratory 2.1 (RP2.1) Panel for the Biofire.

Article Title: Multicenter Evaluation of the QIAstat‐Dx and the BioFire Multiplex Panel Tests for the Detection of Respiratory Pathogens
Article Snippet: Among those are the BioFire respiratory multiplex panel version 2.1 (BioFire‐RP2.1) and the QIAstat‐Dx respiratory panel version 2.0 (QIAstat‐Dx‐RP2.0), generating results from 23 different respiratory targets, including SARS‐CoV‐2 in approximately 1 h. In this prospective multicenter study, we conducted a comparative evaluation of the BioFire‐RP2.1 and QIAstat‐Dx‐RP2.0 multiplex panel tests using 269 respiratory clinical specimens, prospectively collected from patients with RTIs.

Article Title: Performance Assessment of a Multiplex Real-Time PCR Assay for Detection of Viruses Causing Respiratory Tract Infections
Article Snippet: We further compared the performance of this test to two different multiplex PCR-based platforms, which detect SARS-CoV-2, Flu A, Flu B, and RSV in a single reaction: an LDT that is based on a TaqMan ® real-time OpenArray ® PCR platform and an FDA-approved in vitro diagnostic (IVD) test, the BioFire ® Respiratory 2.1 (RP2.1) Panel.

Article Title: Clinical Features and Genomic Characteristics of Post-pandemic Human Metapneumovirus Infections in Hospitalized Taiwanese Children
Article Snippet: 76 In Study 2, we retrieved medical records retrospectively from all hospitalized HMPV-77 infected children confirmed either by the BIOFIRE® Respiratory 2.1 (RP2.1) Panel or 78 the above-mentioned study.

Article Title: Performance Assessment of a Multiplex Real-Time PCR Assay for Detection of Viruses Causing Respiratory Tract Infections
Article Snippet: While the BioFire ® Respiratory 2.1 (RP2.1) Panel mainly detects viral pathogens associated with respiratory illnesses and four bacterial causes of atypical pneumonia, the OA LDT covers, in addition, a broader range of bacterial pathogens involved in respiratory tract infections.

Article Title: Multicenter Evaluation of the QIAstat-Dx and the BioFire Multiplex Panel Tests for the Detection of Respiratory Pathogens.
Article Snippet: Among those are the BioFire respiratory multiplex panel version 2.1 (BioFire‐RP2.1) and the QIAstat‐Dx respiratory panel version 2.0 (QIAstat‐Dx‐RP2.0), generating results from 23 different respiratory targets, including SARS‐CoV‐2 in approximately 1 h. In this prospective multicenter study, we conducted a comparative evaluation of the BioFire‐RP2.1 and QIAstat‐Dx‐RP2.0 multiplex panel tests using 269 respiratory clinical specimens, prospectively collected from patients with RTIs.

Comparison:

Article Title: P-2177. The Prevalence of Respiratory Viral Pathogen Detection on Nasopharyngeal Specimens Evaluated by Multiplex Polymerase Chain Reaction Among Asymptomatic Children
Article Snippet: Participant Findings by Multiplex PCR Positivity in 20 Peds RECON Participants at Enrollment Legend: += positive -= Negative ^= Rhinovirus/Enterovirus and Parainfluenza 3 #=Number NS= not significant, p-value ≥ 0.05 Peds RECON- Pediatric Respiratory Co-infection and Immunologic Response Study NP= Nasopharyngeal (NP) M-PCR= Multiplex Polymerase Chain Reaction, Nasopharyngeal specimens were processed using the BioFire® Respiratory 2.1 (RP2.1) Panel PBMC=Peripheral Blood Mononuclear Cells

Article Title: P-2177. The Prevalence of Respiratory Viral Pathogen Detection on Nasopharyngeal Specimens Evaluated by Multiplex Polymerase Chain Reaction Among Asymptomatic Children
Article Snippet: Demographic and Clinical Characteristics of 20 Children at Enrollment in the Pediatric Respiratory Co-infection and Immunologic Response Study (Peds RECON) Legend: ^= Nasopharyngeal specimens were processed using the BioFire® Respiratory 2.1 (RP2.1) Panel * = within 10 days of the participant’s enrollment visit + = Symptoms queried: fever, headache, runny or dripping nose, sore or painful throat, trouble breathing/shortness of breath, chest tightness/pain, dizziness, coughing, nausea, vomiting, diarrhea, clingy, fussy, decreased energy level #= Among 15 participants where blood sample was available; 4 of 7 participants with positive M-PCR and 11 of 13 participants with negative M-PCR NP=Nasopharyngeal; SD= Standard deviation; M- PCR= Multiplex Polymerase Chain Reaction

Article Title: Evaluation of molecular detection for respiratory syncytial viruses in World Health Organization Europe region laboratories, 2020-2023.
Article Snippet: For bioMérieux, not only are there different assays, but also different diagnostic platforms: SARS-CoV-2 FluA/FluB/RSV R-Gene for qRT-PCR hardware, or the Respiratory 2.1 (RP2.1) Panel for the Biofire.

Article Title: Multicenter Evaluation of the QIAstat‐Dx and the BioFire Multiplex Panel Tests for the Detection of Respiratory Pathogens
Article Snippet: Among those are the BioFire respiratory multiplex panel version 2.1 (BioFire‐RP2.1) and the QIAstat‐Dx respiratory panel version 2.0 (QIAstat‐Dx‐RP2.0), generating results from 23 different respiratory targets, including SARS‐CoV‐2 in approximately 1 h. In this prospective multicenter study, we conducted a comparative evaluation of the BioFire‐RP2.1 and QIAstat‐Dx‐RP2.0 multiplex panel tests using 269 respiratory clinical specimens, prospectively collected from patients with RTIs.

Article Title: Performance Assessment of a Multiplex Real-Time PCR Assay for Detection of Viruses Causing Respiratory Tract Infections
Article Snippet: We further compared the performance of this test to two different multiplex PCR-based platforms, which detect SARS-CoV-2, Flu A, Flu B, and RSV in a single reaction: an LDT that is based on a TaqMan ® real-time OpenArray ® PCR platform and an FDA-approved in vitro diagnostic (IVD) test, the BioFire ® Respiratory 2.1 (RP2.1) Panel.

Article Title: Clinical Features and Genomic Characteristics of Post-pandemic Human Metapneumovirus Infections in Hospitalized Taiwanese Children
Article Snippet: 76 In Study 2, we retrieved medical records retrospectively from all hospitalized HMPV-77 infected children confirmed either by the BIOFIRE® Respiratory 2.1 (RP2.1) Panel or 78 the above-mentioned study.

Article Title: Performance Assessment of a Multiplex Real-Time PCR Assay for Detection of Viruses Causing Respiratory Tract Infections
Article Snippet: While the BioFire ® Respiratory 2.1 (RP2.1) Panel mainly detects viral pathogens associated with respiratory illnesses and four bacterial causes of atypical pneumonia, the OA LDT covers, in addition, a broader range of bacterial pathogens involved in respiratory tract infections.

Article Title: Multicenter Evaluation of the QIAstat-Dx and the BioFire Multiplex Panel Tests for the Detection of Respiratory Pathogens.
Article Snippet: Among those are the BioFire respiratory multiplex panel version 2.1 (BioFire‐RP2.1) and the QIAstat‐Dx respiratory panel version 2.0 (QIAstat‐Dx‐RP2.0), generating results from 23 different respiratory targets, including SARS‐CoV‐2 in approximately 1 h. In this prospective multicenter study, we conducted a comparative evaluation of the BioFire‐RP2.1 and QIAstat‐Dx‐RP2.0 multiplex panel tests using 269 respiratory clinical specimens, prospectively collected from patients with RTIs.

Bacteria:

Article Title: P-2177. The Prevalence of Respiratory Viral Pathogen Detection on Nasopharyngeal Specimens Evaluated by Multiplex Polymerase Chain Reaction Among Asymptomatic Children
Article Snippet: Participant Findings by Multiplex PCR Positivity in 20 Peds RECON Participants at Enrollment Legend: += positive -= Negative ^= Rhinovirus/Enterovirus and Parainfluenza 3 #=Number NS= not significant, p-value ≥ 0.05 Peds RECON- Pediatric Respiratory Co-infection and Immunologic Response Study NP= Nasopharyngeal (NP) M-PCR= Multiplex Polymerase Chain Reaction, Nasopharyngeal specimens were processed using the BioFire® Respiratory 2.1 (RP2.1) Panel PBMC=Peripheral Blood Mononuclear Cells

Article Title: P-2177. The Prevalence of Respiratory Viral Pathogen Detection on Nasopharyngeal Specimens Evaluated by Multiplex Polymerase Chain Reaction Among Asymptomatic Children
Article Snippet: Demographic and Clinical Characteristics of 20 Children at Enrollment in the Pediatric Respiratory Co-infection and Immunologic Response Study (Peds RECON) Legend: ^= Nasopharyngeal specimens were processed using the BioFire® Respiratory 2.1 (RP2.1) Panel * = within 10 days of the participant’s enrollment visit + = Symptoms queried: fever, headache, runny or dripping nose, sore or painful throat, trouble breathing/shortness of breath, chest tightness/pain, dizziness, coughing, nausea, vomiting, diarrhea, clingy, fussy, decreased energy level #= Among 15 participants where blood sample was available; 4 of 7 participants with positive M-PCR and 11 of 13 participants with negative M-PCR NP=Nasopharyngeal; SD= Standard deviation; M- PCR= Multiplex Polymerase Chain Reaction

Article Title: Evaluation of molecular detection for respiratory syncytial viruses in World Health Organization Europe region laboratories, 2020-2023.
Article Snippet: For bioMérieux, not only are there different assays, but also different diagnostic platforms: SARS-CoV-2 FluA/FluB/RSV R-Gene for qRT-PCR hardware, or the Respiratory 2.1 (RP2.1) Panel for the Biofire.

Article Title: Multicenter Evaluation of the QIAstat‐Dx and the BioFire Multiplex Panel Tests for the Detection of Respiratory Pathogens
Article Snippet: Among those are the BioFire respiratory multiplex panel version 2.1 (BioFire‐RP2.1) and the QIAstat‐Dx respiratory panel version 2.0 (QIAstat‐Dx‐RP2.0), generating results from 23 different respiratory targets, including SARS‐CoV‐2 in approximately 1 h. In this prospective multicenter study, we conducted a comparative evaluation of the BioFire‐RP2.1 and QIAstat‐Dx‐RP2.0 multiplex panel tests using 269 respiratory clinical specimens, prospectively collected from patients with RTIs.

Article Title: Performance Assessment of a Multiplex Real-Time PCR Assay for Detection of Viruses Causing Respiratory Tract Infections
Article Snippet: We further compared the performance of this test to two different multiplex PCR-based platforms, which detect SARS-CoV-2, Flu A, Flu B, and RSV in a single reaction: an LDT that is based on a TaqMan ® real-time OpenArray ® PCR platform and an FDA-approved in vitro diagnostic (IVD) test, the BioFire ® Respiratory 2.1 (RP2.1) Panel.

Article Title: Clinical Features and Genomic Characteristics of Post-pandemic Human Metapneumovirus Infections in Hospitalized Taiwanese Children
Article Snippet: 76 In Study 2, we retrieved medical records retrospectively from all hospitalized HMPV-77 infected children confirmed either by the BIOFIRE® Respiratory 2.1 (RP2.1) Panel or 78 the above-mentioned study.

Article Title: Performance Assessment of a Multiplex Real-Time PCR Assay for Detection of Viruses Causing Respiratory Tract Infections
Article Snippet: While the BioFire ® Respiratory 2.1 (RP2.1) Panel mainly detects viral pathogens associated with respiratory illnesses and four bacterial causes of atypical pneumonia, the OA LDT covers, in addition, a broader range of bacterial pathogens involved in respiratory tract infections.

Article Title: Multicenter Evaluation of the QIAstat-Dx and the BioFire Multiplex Panel Tests for the Detection of Respiratory Pathogens.
Article Snippet: Among those are the BioFire respiratory multiplex panel version 2.1 (BioFire‐RP2.1) and the QIAstat‐Dx respiratory panel version 2.0 (QIAstat‐Dx‐RP2.0), generating results from 23 different respiratory targets, including SARS‐CoV‐2 in approximately 1 h. In this prospective multicenter study, we conducted a comparative evaluation of the BioFire‐RP2.1 and QIAstat‐Dx‐RP2.0 multiplex panel tests using 269 respiratory clinical specimens, prospectively collected from patients with RTIs.

In Vitro:

Article Title: P-2177. The Prevalence of Respiratory Viral Pathogen Detection on Nasopharyngeal Specimens Evaluated by Multiplex Polymerase Chain Reaction Among Asymptomatic Children
Article Snippet: Participant Findings by Multiplex PCR Positivity in 20 Peds RECON Participants at Enrollment Legend: += positive -= Negative ^= Rhinovirus/Enterovirus and Parainfluenza 3 #=Number NS= not significant, p-value ≥ 0.05 Peds RECON- Pediatric Respiratory Co-infection and Immunologic Response Study NP= Nasopharyngeal (NP) M-PCR= Multiplex Polymerase Chain Reaction, Nasopharyngeal specimens were processed using the BioFire® Respiratory 2.1 (RP2.1) Panel PBMC=Peripheral Blood Mononuclear Cells

Article Title: P-2177. The Prevalence of Respiratory Viral Pathogen Detection on Nasopharyngeal Specimens Evaluated by Multiplex Polymerase Chain Reaction Among Asymptomatic Children
Article Snippet: Demographic and Clinical Characteristics of 20 Children at Enrollment in the Pediatric Respiratory Co-infection and Immunologic Response Study (Peds RECON) Legend: ^= Nasopharyngeal specimens were processed using the BioFire® Respiratory 2.1 (RP2.1) Panel * = within 10 days of the participant’s enrollment visit + = Symptoms queried: fever, headache, runny or dripping nose, sore or painful throat, trouble breathing/shortness of breath, chest tightness/pain, dizziness, coughing, nausea, vomiting, diarrhea, clingy, fussy, decreased energy level #= Among 15 participants where blood sample was available; 4 of 7 participants with positive M-PCR and 11 of 13 participants with negative M-PCR NP=Nasopharyngeal; SD= Standard deviation; M- PCR= Multiplex Polymerase Chain Reaction

Article Title: Evaluation of molecular detection for respiratory syncytial viruses in World Health Organization Europe region laboratories, 2020-2023.
Article Snippet: For bioMérieux, not only are there different assays, but also different diagnostic platforms: SARS-CoV-2 FluA/FluB/RSV R-Gene for qRT-PCR hardware, or the Respiratory 2.1 (RP2.1) Panel for the Biofire.

Article Title: Multicenter Evaluation of the QIAstat‐Dx and the BioFire Multiplex Panel Tests for the Detection of Respiratory Pathogens
Article Snippet: Among those are the BioFire respiratory multiplex panel version 2.1 (BioFire‐RP2.1) and the QIAstat‐Dx respiratory panel version 2.0 (QIAstat‐Dx‐RP2.0), generating results from 23 different respiratory targets, including SARS‐CoV‐2 in approximately 1 h. In this prospective multicenter study, we conducted a comparative evaluation of the BioFire‐RP2.1 and QIAstat‐Dx‐RP2.0 multiplex panel tests using 269 respiratory clinical specimens, prospectively collected from patients with RTIs.

Article Title: Performance Assessment of a Multiplex Real-Time PCR Assay for Detection of Viruses Causing Respiratory Tract Infections
Article Snippet: We further compared the performance of this test to two different multiplex PCR-based platforms, which detect SARS-CoV-2, Flu A, Flu B, and RSV in a single reaction: an LDT that is based on a TaqMan ® real-time OpenArray ® PCR platform and an FDA-approved in vitro diagnostic (IVD) test, the BioFire ® Respiratory 2.1 (RP2.1) Panel.

Article Title: Clinical Features and Genomic Characteristics of Post-pandemic Human Metapneumovirus Infections in Hospitalized Taiwanese Children
Article Snippet: 76 In Study 2, we retrieved medical records retrospectively from all hospitalized HMPV-77 infected children confirmed either by the BIOFIRE® Respiratory 2.1 (RP2.1) Panel or 78 the above-mentioned study.

Article Title: Performance Assessment of a Multiplex Real-Time PCR Assay for Detection of Viruses Causing Respiratory Tract Infections
Article Snippet: While the BioFire ® Respiratory 2.1 (RP2.1) Panel mainly detects viral pathogens associated with respiratory illnesses and four bacterial causes of atypical pneumonia, the OA LDT covers, in addition, a broader range of bacterial pathogens involved in respiratory tract infections.

Article Title: Multicenter Evaluation of the QIAstat-Dx and the BioFire Multiplex Panel Tests for the Detection of Respiratory Pathogens.
Article Snippet: Among those are the BioFire respiratory multiplex panel version 2.1 (BioFire‐RP2.1) and the QIAstat‐Dx respiratory panel version 2.0 (QIAstat‐Dx‐RP2.0), generating results from 23 different respiratory targets, including SARS‐CoV‐2 in approximately 1 h. In this prospective multicenter study, we conducted a comparative evaluation of the BioFire‐RP2.1 and QIAstat‐Dx‐RP2.0 multiplex panel tests using 269 respiratory clinical specimens, prospectively collected from patients with RTIs.



Similar Products

96
DiaSorin Biotechnology eplex respiratory pathogen panel 2 rp2 panel
Eplex Respiratory Pathogen Panel 2 Rp2 Panel, supplied by DiaSorin Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/respiratory+panel+2+(rp2/NxTAG+Respiratory+Pathogen+Panel/pm39857007-234-35-47
Average 96 stars, based on 1 article reviews
eplex respiratory pathogen panel 2 rp2 panel - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier

94
ZeptoMetrix corporation nattrol respiratory panel 2 1 rp2 1
Nattrol Respiratory Panel 2 1 Rp2 1, supplied by ZeptoMetrix corporation, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/respiratory+panel+2+(rp2/NATtrol+Respiratory+Panel+2%2E1/pmc11228040-150-40-45
Average 94 stars, based on 1 article reviews
nattrol respiratory panel 2 1 rp2 1 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

94
ZeptoMetrix corporation nattroltm respiratory panel 2 1 rp2 1
Nattroltm Respiratory Panel 2 1 Rp2 1, supplied by ZeptoMetrix corporation, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/respiratory+panel+2+(rp2/NATtrol+Respiratory+Panel+2%2E1/pm38972920-65-40-45
Average 94 stars, based on 1 article reviews
nattroltm respiratory panel 2 1 rp2 1 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

90
BioFire Defense filmarray respiratory 2 (rp2) panel
Filmarray Respiratory 2 (Rp2) Panel, supplied by BioFire Defense, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/respiratory+panel+2+(rp2/filmarray+respiratory+panel/pm38666607-6-23-22
Average 90 stars, based on 1 article reviews
filmarray respiratory 2 (rp2) panel - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
bioMerieux gmbh filmarray respiratory panel 2 (rp2)
Filmarray Respiratory Panel 2 (Rp2), supplied by bioMerieux gmbh, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/respiratory+panel+2+(rp2/filmarray+respiratory+panel/10__55522_slash_jmpas__v12i6__5666-57-15-20
Average 90 stars, based on 1 article reviews
filmarray respiratory panel 2 (rp2) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
BioFire Defense respiratory panel 2 (rp2
Respiratory Panel 2 (Rp2, supplied by BioFire Defense, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/respiratory+panel+2+(rp2/respiratory+panel+2+1/10__3389_slash_fviro__2023__1156012-54-14-14
Average 90 stars, based on 1 article reviews
respiratory panel 2 (rp2 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

94
ZeptoMetrix corporation nattroltm respiratory panel 2 1 rp2 1 controls
Nattroltm Respiratory Panel 2 1 Rp2 1 Controls, supplied by ZeptoMetrix corporation, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/respiratory+panel+2+(rp2/NATtrol+Respiratory+Panel+2%2E1/pm36825940-70-1-9
Average 94 stars, based on 1 article reviews
nattroltm respiratory panel 2 1 rp2 1 controls - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

Image Search Results